[Novel therapeutic strategy for neurogenesis in the neurodegenerative disorders].
Fukunaga
Kohji
K
fukunaga@mail.pharm.tohoku.ac.jp
Shioda
Norifumi
N
Morioka
Motohiro
M
Han
Feng
F
D000818:Animals; D003071:Cognition / Q000187:drug effects; D000077265:Donepezil; D015195:Drug Design; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006624:Hippocampus / Q000502:physiology; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use; D016651:Lithium Carbonate / Q000494:pharmacology / Q000627:therapeutic use; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D013268:Stimulation, Chemical; D014635:Valproic Acid / Q000494:pharmacology / Q000627:therapeutic use; D017968:Vanadium Compounds / Q000494:pharmacology / Q000627:therapeutic use
D007189:Indans; D010880:Piperidines; D017968:Vanadium Compounds; D016651:Lithium Carbonate; D014635:Valproic Acid; D000077265:Donepezil; D048049:Extracellular Signal-Regulated MAP Kinases